Navigation Links
Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
Date:2/24/2009

KANSAS CITY, Mo., Feb. 24 /PRNewswire/ -- An investor group in Trinity Biotech plc (Nasdaq: TRIB), an Irish based developer and manufacturer of diagnostic products, has petitioned the Office of the Director of Corporate Enforcement to facilitate compliance with key company law provisions designed to permit communication between shareholders and prospective shareholders.

The petition as filed asserts that Irish-based independent directors, Peter Coyne of Allied Irish Bank, and Dr. Jim Walsh, together with Chairman and CEO, Ronan O'Caoimh have breached Irish Company Law by blocking access to information requested by shareholders wishing to convert ADRs (American Depository Receipts) to the Irish shares they represent. The investor group has requested ODCE support of a formal investigation of the above named individuals for violation of Company Law and to pursue corrective action against this illegal behavior.

Commenting on the news, Mr. Reidy stated, "We are disappointed that the current Board has disregarded not only the wishes of shareholders but its obligations to respond to shareholder requests for the calling of an EGM (Extraordinary General Meeting). We are particularly displeased by the board's refusal to provide periodic notification of changes in registered ownership of company shares, which we view as a basic right protected under Irish securities law."

Contact: Tom Reidy, 816-260-8476, tjreidy3@hotmail.com


'/>"/>
SOURCE KC Investor Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
2. Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
3. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
4. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
5. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
6. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
7. BioMS Medical to present at BIO CEO and Investor Conference
8. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
11. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):